ALN-RSV01: Phase IIb started

Alnylam began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 0.6 mg/kg inhaled ALN-RSV01 given once daily for 5 days in about 76 patients. The compound is delivered with...